MoonLake Immunotherapeutics’ Sonelokimab Shows Promise in Psoriatic Arthritis and HS, Meriting a Buy Rating

LifeSci Capital analyst Rami Katkhuda maintained a Buy rating on MoonLake Immunotherapeutics (MLTX – Research Report) today and set a price target of $75.00.

Rami Katkhuda has given his Buy rating due to a combination of factors including the promising clinical profile of MoonLake Immunotherapeutics’ drug sonelokimab, as evidenced by recent study results. The drug has shown significant efficacy in the treatment of Psoriatic Arthritis (PsA) based on data from the MIRA and ARGO studies, demonstrating higher efficacy thresholds and improvements over the reference drug adalimumab. Notably, the drug has achieved impressive composite scores and response rates across various endpoints, indicating a strong potential for treatment effectiveness.
Furthermore, sonelokimab’s performance in achieving Minimal Disease Activity in patients and its potential market opportunity in Hidradenitis Suppurativa (HS) have contributed to the positive outlook. The management’s strategic plans for phase III development and indication expansion bolster the case for a Buy rating. The drug’s potential in both PsA and HS, coupled with the competitive advantages it may offer over existing treatments, underpin Katkhuda’s optimism for MoonLake Immunotherapeutics’ future prospects and its stock valuation.

In another report released on April 23, H.C. Wainwright also reiterated a Buy rating on the stock with a $100.00 price target.

TipRanks tracks over 100,000 company insiders, identifying the select few who excel in timing their transactions. By upgrading to TipRanks Premium, you will gain access to this exclusive data and discover crucial insights to guide your investment decisions. Begin your TipRanks Premium journey today.

MoonLake Immunotherapeutics (MLTX) Company Description:

Helix Acquisition Corp is a blank check company.